Publications
2024
Influence of highly effective modulator therapy on the sputum proteome in cystic fibrosis.
Maher, R. E., Barry, P. J., Emmott, E., Jones, A. M., Lin, L., McNamara, P. S., . . . Lord, R. W. (2024). Influence of highly effective modulator therapy on the sputum proteome in cystic fibrosis.. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 23(2), 269-277. doi:10.1016/j.jcf.2023.10.019
2023
Investigating markers of pulmonary aspiration in bronchoalveolar lavage from children with severe neurodisability
2022
The relationship between lung disease severity and the sputum proteome in cystic fibrosis
Maher, R. E., Barrett, E., Beynon, R. J., Harman, V. M., Jones, A. M., McNamara, P. S., . . . Lord, R. W. (2022). The relationship between lung disease severity and the sputum proteome in cystic fibrosis. RESPIRATORY MEDICINE, 204. doi:10.1016/j.rmed.2022.107002
Electrospray ionization: “We taught elephants to fly”
Maher, R., & Emmott, E. (2022). Electrospray ionization: “We taught elephants to fly”. The Biochemist, 44(5), 5-8. doi:10.1042/bio_2022_127
Quantitative proteomic analysis of bronchoalveolar lavage fluid in West Highland white terriers with canine idiopathic pulmonary fibrosis
Maher, R. E., Maatta, M., Beynon, R. J., Laurila, H. P., McNamara, P. S., & Rajamaki, M. M. (2022). Quantitative proteomic analysis of bronchoalveolar lavage fluid in West Highland white terriers with canine idiopathic pulmonary fibrosis. BMC VETERINARY RESEARCH, 18(1). doi:10.1186/s12917-022-03202-x
2021
Biomarkers for inflammatory lung disease
Maher, R. (2021, November 30). Biomarkers for inflammatory lung disease.
2019
THE SPUTUM PROTEOME AND ITS RELATIONSHIP TO CYSTIC FIBROSIS LUNG DISEASE: USING GLOBAL PROTEOMICS TO DEVELOP CLINICALLY USEFUL BIOMARKERS
Lord, R. W., Maher, R. E., Harman, V., Bianco, B., Whorwell, P. J., McNamara, P. S., . . . Jones, A. M. (2019). THE SPUTUM PROTEOME AND ITS RELATIONSHIP TO CYSTIC FIBROSIS LUNG DISEASE: USING GLOBAL PROTEOMICS TO DEVELOP CLINICALLY USEFUL BIOMARKERS. In THORAX Vol. 74 (pp. A12-A13). doi:10.1136/thorax-2019-BTSabstracts2019.24
2018
THE USE OF QUANTITATIVE PROTEOMICS TO ASSESS THE IMPACT OF REFLUX ASPIRATION ON CYSTIC FIBROSIS LUNG DISEASE
Lord, R. W., Maher, R. E., Harman, V. M., Treadway, S., Bianco, B., Barry, P. J., . . . Jones, A. M. (2018). THE USE OF QUANTITATIVE PROTEOMICS TO ASSESS THE IMPACT OF REFLUX ASPIRATION ON CYSTIC FIBROSIS LUNG DISEASE. In THORAX Vol. 73 (pp. A162). doi:10.1136/thorax-2018-212555.270